Table 4.

Antiinfective prophylaxis in HDC/ASCT recipients

Population	Intention	Intervention	SoR	QoE	References
Any	To prevent infection	Any fluoroquinolone	A	I	Bucaneve NEJM (2005) [58]
Any	To reduce mortality	Any fluoroquinolone	C	I	Bucaneve NEJM (2005) [58] Signorelli TID (2020) [10]
Any	To prevent IFD	Primary prophylaxis with mould active antifungal	D	II	Van Burik CID (2004) [63]
Any	To prevent invasive candidiasis	Primary prophylaxis with fluconazole 400 mg/d	D	I	Van Burik CID (2004) [63] Rotstein CID (1999) [62] Goodman NEJM (1992) [115]
Patients with previous IFD	To prevent recurrence of IFD	Secondary prophylaxis with the last successfully used antifungal	A	IIt	Cornely Mycoses (2019) [116] Sun BBMT (2015) [117]
Any	To prevent invasive fungal infection	Protective room ventilation e.g. HEPA filtration	C	IIu	Vokurka JCN (2013) [65] Dadd J Ped Oncol Nurs (2003) [118]
Any	To prevent PJP	Cotrimoxazole	B	IIr	Stern Cochrane (2014) [66]
Any	To prevent HSV reactivation	Acyclovir/valacyclovir	A	IIt	Kawamura IJH (2015) [70] Glenny Cochrane Database (2009) [119]
CD34-selected or enriched transplant	To prevent HSV reactivation	Acyclovir/valacyclovir	A	IIu	Van Laar JAMA (2014) [34] Lin Int J Hematol (2008) [72]
Seropositive for VZV	To prevent VZV reactivation	Vaccination	A	I	Winston Lancet (2018) [69] Dagnew Lancet ID (2019) [120]
Any	To prevent VZV reactivation	Acyclovir	A	IIu	Winston Lancet (2018) [69] Kawamura IJH (2015) [70] Sahoo BBMT (2017) [121] Seo Antivir Res (2017) [122]
CD34-selected or enriched transplant	To prevent VZV reactivation	Acyclovir	A	IIu	Crippa BBMT (2002) [123]
Any	To reduce CMV infection/disease	CMV prophylaxis (e.g. with foscarnet or acyclovir)	D	IIu	Boeckh JID (1995) [124]
HBs antigen or anti-HBc antibody positive	To prevent hepatitis B reactivation	Tenofovir or entecavir	A	IIt	Huang JCO (2013) [125] Lau Gastroenterol (2003) [126]